This phase II trial is trying to find out how effective it is to treat patients, diagnosed with T-Cell Prolymphocytic Leukemia, with a targeted therapy (Ibrutinib) in combination with chemotherapy (Venetoclax).
This trial is treating patients with T-cell prolymphocytic leukemia .
This is a systemic therapy trial.
You may be able to join this trial if:
- You have been diagnosed with cancer, but have not received any treatment.
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Prospective, Open-Label, Single-Arm, Phase 2, Multicenter Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Subjects With T-Cell Prolymphocytic Leukemia
Commercial Sponsor
AbbVie
Summary
Eligible patients will receive oral Venetoclax (400mg) in combination with oral Ibrutinib (420mg) once daily.
Recruiting Hospitals Read More